HCV Core Protein Induces Chemokine CCL2 and CXCL10 Expression Through NF-κB Signaling Pathway in Macrophages.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 02 02 2021
accepted: 16 08 2021
entrez: 17 9 2021
pubmed: 18 9 2021
medline: 21 10 2021
Statut: epublish

Résumé

HCV core protein is the first structural protein synthesized during hepatitis C virus (HCV) infection and replication. It is released from virus infected liver cells and mediates multiple functions to affect host cell response. The innate immune response is the first line of defense against viral infection. After HCV infection, Kupffer cells (KCs) which are liver macrophages play an important role in host innate immune response. Kupffer cells act as phagocytes and release different cytokines and chemokines to counter viral infection and regulate inflammation and fibrosis in liver. Earlier, we have demonstrated that HCV core protein interacts with gC1qR and activates MAPK, NF-κB and PI3K/AKT pathways in macrophages. In this study, we explored the effect of HCV core protein on CCL2 and CXCL10 expression in macrophages and the signaling pathways involved. Upon silencing of gC1qR, we observed a significant decrease expression of CCL2 and CXCL10 in macrophages in the presence of HCV core protein. Inhibiting NF-κB pathway, but not P38, JNK, ERK and AKT pathways greatly reduced the expression of CCL2 and CXCL10. Therefore, our results indicate that interaction of HCV core protein with gC1qR could induce CCL2 and CXCL10 secretion in macrophages

Identifiants

pubmed: 34531848
doi: 10.3389/fimmu.2021.654998
pmc: PMC8438213
doi:

Substances chimiques

Chemokine CCL2 0
Chemokine CXCL10 0
NF-kappa B 0
Viral Core Proteins 0
nucleocapsid protein, Hepatitis C virus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

654998

Informations de copyright

Copyright © 2021 Song, Gao, Wang, Raja, Zhang, Yang, Li, Yao and Wei.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Gastroenterology. 2010 Jan;138(1):325-35.e1-2
pubmed: 19747917
Cells. 2019 Apr 25;8(4):
pubmed: 31027182
Hepatology. 2006 Sep;44(3):527-35
pubmed: 16941688
Nat Med. 2013 Jul;19(7):850-8
pubmed: 23836235
Mediterr J Hematol Infect Dis. 2016 Jan 01;8(1):e2016003
pubmed: 26740864
J Immunol. 1998 Apr 1;160(7):3534-42
pubmed: 9531316
Immunol Res. 2006;34(3):211-27
pubmed: 16891672
Front Cell Dev Biol. 2020 Jul 03;8:498
pubmed: 32719792
Immunology. 2008 Oct;125(2):197-207
pubmed: 18397267
J Immunol. 2011 Mar 1;186(5):3093-103
pubmed: 21263070
J Infect Dis. 2010 Sep 15;202(6):853-61
pubmed: 20677943
PLoS Pathog. 2010 Jul 01;6:e1000975
pubmed: 20617170
Oncotarget. 2018 Jan 9;9(12):10784-10807
pubmed: 29535843
Hepatology. 2012 Mar;55(3):666-75
pubmed: 22030901
Cell Mol Immunol. 2016 May;13(3):316-27
pubmed: 26908374
Annu Rev Pharmacol Toxicol. 2008;48:171-97
pubmed: 17883327
Cell Mol Immunol. 2018 Apr;15(4):324-334
pubmed: 29375126
Nature. 2005 Aug 18;436(7053):930-2
pubmed: 16107831
J Hepatol. 2014 May;60(5):1090-6
pubmed: 24412603
J Clin Invest. 1995 Apr;95(4):1569-78
pubmed: 7706463
PLoS One. 2014 Jul 30;9(7):e103219
pubmed: 25076408
Hepat Mon. 2015 Aug 30;15(8):e29282
pubmed: 26322111
Clin Microbiol Infect. 2011 Feb;17(2):107-15
pubmed: 21091831
Mol Immunol. 2016 Jun;74:18-26
pubmed: 27111569
Methods Mol Biol. 2017;1639:161-171
pubmed: 28752456
J Vis Exp. 2015 Aug 18;(102):e52989
pubmed: 26327223
Gastroenterology. 2014 Sep;147(3):577-594.e1
pubmed: 25066692
Clin Gastroenterol Hepatol. 2014 Dec;12(12):2113-20.e1-3
pubmed: 24815325
J Immunol. 2001 Nov 1;167(9):5264-72
pubmed: 11673541
Sci Rep. 2016 Dec 21;6:39520
pubmed: 28000758
Immunity. 2000 Feb;12(2):121-7
pubmed: 10714678
Front Immunol. 2021 Jun 21;12:679458
pubmed: 34234780
Nat Rev Microbiol. 2011 Apr;9(4):291-306
pubmed: 21383764
Int Immunol. 2012 Feb;24(2):97-106
pubmed: 22190574
EMBO J. 2000 Apr 3;19(7):1458-66
pubmed: 10747014
J Virol. 2015 Oct 14;90(1):300-7
pubmed: 26468521
Clin Chem Lab Med. 2018 May 24;56(6):880-888
pubmed: 29702484
J Immunol. 1995 Sep 1;155(5):2614-9
pubmed: 7650391
J Atheroscler Thromb. 2004;11(2):88-97
pubmed: 15153668
J Hepatol. 2013 Oct;59(4):701-8
pubmed: 23770038
Nat Rev Microbiol. 2013 Jul;11(7):482-96
pubmed: 23748342
Cell Mol Immunol. 2015 Nov;12(6):743-9
pubmed: 25531392
Lancet. 2003 Dec 20;362(9401):2095-100
pubmed: 14697814
J Gen Virol. 1998 Jul;79 ( Pt 7):1677-85
pubmed: 9680131
Front Immunol. 2018 Apr 04;9:557
pubmed: 29670611
Immunol Res. 2014 Oct;60(1):1-10
pubmed: 24557493
Mol Cell Biol. 1994 Aug;14(8):5349-59
pubmed: 8035813
Mediators Inflamm. 2018 May 27;2018:8578051
pubmed: 29977152
Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1530-5
pubmed: 19164550
Cells. 2020 Jul 06;9(7):
pubmed: 32640727
PLoS One. 2011;6(5):e19664
pubmed: 21637332
Gut Liver. 2011 Dec;5(4):506-12
pubmed: 22195251
Clin Transplant. 2014 May;28(5):569-78
pubmed: 24750380
PLoS Pathog. 2013;9(4):e1003330
pubmed: 23633957
Lancet Infect Dis. 2005 Sep;5(9):558-67
pubmed: 16122679
Oncotarget. 2016 Jun 7;7(23):33796-808
pubmed: 27183919
Hepatology. 2004 Jan;39(1):5-19
pubmed: 14752815
J Gen Virol. 2008 Oct;89(Pt 10):2507-2517
pubmed: 18796720
J Infect Dis. 2011 Sep 15;204(6):832-6
pubmed: 21849280
PLoS Pathog. 2019 Feb 27;15(2):e1007593
pubmed: 30811485
Nature. 2005 Aug 18;436(7053):973-8
pubmed: 16107838
J Clin Invest. 2000 Nov;106(10):1239-49
pubmed: 11086025
J Leukoc Biol. 2003 Sep;74(3):360-9
pubmed: 12949239
Semin Liver Dis. 2007 Nov;27(4):339-50
pubmed: 17979071
J Viral Hepat. 2011 Sep;18(9):608-18
pubmed: 20565573
J Virol. 2004 Jun;78(12):6409-19
pubmed: 15163734

Auteurs

Xiaotian Song (X)

Department of Immunology, Hebei Medical University, Shijiazhuang, China.
Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Shijiazhuang, China.

Xue Gao (X)

Department of Immunology, Hebei Medical University, Shijiazhuang, China.
Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Shijiazhuang, China.

Yadong Wang (Y)

Department of Infectious Diseases, The Third Hospital of Hebei Medical University, Shijiazhuang, China.

Rameez Raja (R)

Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States.

Yaoyu Zhang (Y)

Department of Immunology, Hebei Medical University, Shijiazhuang, China.
Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Shijiazhuang, China.

Shulin Yang (S)

Department of Immunology, Hebei Medical University, Shijiazhuang, China.
Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Shijiazhuang, China.

Miao Li (M)

Department of Immunology, Hebei Medical University, Shijiazhuang, China.
Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Shijiazhuang, China.

Zhiyan Yao (Z)

Department of Immunology, Hebei Medical University, Shijiazhuang, China.
Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Shijiazhuang, China.

Lin Wei (L)

Department of Immunology, Hebei Medical University, Shijiazhuang, China.
Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Shijiazhuang, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH